Table 1 Demographic and clinical characteristics of eyes treated with ranibizumab and aflibercept.

From: Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy

Characteristics

Total eyes

Typical nAMD

PCV

Ranibizumab

Aflibercept

p value

Ranibizumab

Aflibercept

p value

Ranibizumab

Aflibercept

p value

Number of eyes

131 eyes of 126 patients

84 eyes of 83 patients

 

66 eyes of 64 patients

45 eyes of 44 patients

 

65 eyes of 62 patients

39 eyes of 39 patients

 

Bilaterality, n (%)

5 (3.8%)

1 (1.2%)

0.617*

2 (3.0%)

1 (2.2%)

0.797*

3 (4.6%)

0 (0.0%)

0.173*

Age (years), mean ± SD

69.79 ± 8.60

70.62 ± 7.87

0.479†

73.85 ± 6.58

72.42 ± 7.10

0.280†

65.68 ± 8.50

68.54 ± 8.29

0.096†

Sex, male (%)

75 (57.3%)

50 (59.5%)

0.742*

41 (62.1%)

22 (48.9%)

0.167*

50 (76.9%)

27 (69.2%)

0.386*

DM, n (%)

18/101 (17.8%)

21/75 (28.0%)

0.108*

13/51 (25.5%)

13/40 (32.5%)

0.463*

5/50 (10.0%)

8/35 (22.9%)

0.105*

HTN, n (%)

44/101 (43.6%)

25/77 (33.3%)

0.169*

27/51 (52.9%)

11/40 (27.5%)

0.015*

17/50 (34.0%)

14/35 (40.0%)

0.572*

Typical nAMD/PCV, n

66/65

45/39

0.648*

      

Baseline VA (LogMAR letter), mean ± SD

52.98 ± 21.41

52.50 ± 21.44

0.872†

49.76 ± 19.64

52.20 ± 20.67

0.530†

56.26 ± 22.75

52.85 ± 22.57

0.459†

VA ≥ 70 letters, n (%)

46 (35.1%)

28 (32.1%)

0.789*

17 (25.8%)

13 (28.9%)

0.715*

29 (44.6%)

15 (38.5%)

0.539*

VA ≤ 35 letters, n (%)

40 (30.5%)

27 (32.1%)

0.804*

26 (37.9%)

16 (35.6%)

0.803*

15 (23.1%)

11 (28.2%)

0.559*

Subretinal hemorrhage, n (%)

30 (22.9%)

10 (11.9%)

0.043*

13 (19.7%)

3 (6.7%)

0.055*

17 (26.2%)

7 (17.9%)

0.336*

Onset (months), mean ± SD

2.57 ± 7.04

3.00 ± 9.00

0.880†

3.69 ± 7.17

13.50 ± 19.09

0.161†

1.70 ± 7.03

0.00 ± 0.00

0.533†

Treatment modality

Anti-VEGF monotherapy, n (%)

128 (97.7%)

86 (100%)

0.158*

65 (98.5%)

45 (100%)

0.407*

63 (96.9%)

39 (100%)

0.269*

Combined with PDT, n (%)

3 (2.3%)

0 (0.0%)

0.158*

1 (1.5%)

0 (0.0%)

0.407*

2 (3.1%)

0 (0.0%)

0.269*

Follow-up period (years), mean ± SD

2.59 ± 1.35

2.71 ± 1.26

0.492†

2.45 ± 1.38

2.69 ± 1.24

0.363†

2.72 ± 1.31

2.74 ± 1.29

0.938†

Completers of 1 year, n (%)

113 (86.3%)

76 (90.5%)

0.355*

56 (84.8%)

42 (93.3%)

0.172*

57 (87.7%)

34 (87.2%)

0.939*

Completers of 2 years, n (%)

86 (60.9%)

64 (76.2%)

0.101*

40 (60.6%)

35 (77.8%)

0.058*

46 (70.8%)

29 (74.4%)

0.693*

Completers of 3 years, n (%)

66 (50.4%)

43 (51.2%)

0.908*

30 (45.5%)

22 (48.9%)

0.722*

36 (55.4%)

21 (53.8%)

0.879*

Completers of 4 years, n (%)

57 (43.5%)

37 (44.0%)

0.938*

27 (40.9%)

19 (42.2%)

0.890*

30 (46.2%)

18 (46.2%)

1.000*

  1. DM diabetes mellitus, HTN hypertension, nAMD neovascular age-related macular degeneration, PCV polypoidal choroidal vasculopathy, VA visual acuity, LogMAR Log minimum angle of resolution, SRH subretinal hemorrhage, Anti-VEGF anti-vascular endothelial growth factor, PDT photodynamic therapy.
  2. *Pearson chi-square test.
  3. †Independent t-test.
Back to article page